These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 36743671)

  • 1. Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report.
    Lijeskić O; Klun I; Stamenov Djaković M; Gligorić N; Štajner T; Srbljanović J; Djurković-Djaković O
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of SARS-Cov-2 neutralizing antibody among Sinopharm Vero Cell (BBIBP-CorV) vaccinated medical students.
    Khadka S; Regmi SM; Subedi N; Poudel A; Bhandari DR; Karn M; Pradhan S; Shrestha P
    Hum Antibodies; 2024 Jul; ():. PubMed ID: 39031351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Side Effects and Efficacy of COVID-19 Vaccines among the Egyptian Population.
    Elgendy MO; El-Gendy AO; Mahmoud S; Mohammed TY; Abdelrahim MEA; Sayed AM
    Vaccines (Basel); 2022 Jan; 10(1):. PubMed ID: 35062770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scleromyxedema in an adult following Sinopharm BBIBP-CorV vaccination: An extremely rare phenomenon.
    Parsaei A; Rezaei SS; Rahmani A; Masoumi M; Dehghanbanadaki H; Norouzi S; Riyahi MM; Tabaraii R; Montazeri SMH
    J Scleroderma Relat Disord; 2023 Jun; 8(2):NP9-NP12. PubMed ID: 37287947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of BBIBP-CorV vaccine on gut microbiota and short-chain fatty acids in mice exposed to bis (2-ethylhexyl) phthalate and dioctyl terephthalate.
    Teng M; Sun J; Zhao L; Li Y; Zhang Z; Zhu W; Zhang Y; Xu F; Xing S; Zhao X; Wu F
    Environ Int; 2024 Jun; 190():108851. PubMed ID: 38941942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study.
    Safarnezhad Tameshkel F; Abedin Dargoush S; Amirkalali B; Javadi S; Ghiaseddin A; Alimohamadi Y; Basi A; Jamshidi Makiani M; Zamani F; Karbalaie Niya MH
    Front Med (Lausanne); 2022; 9():1095194. PubMed ID: 36743671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study.
    Stoma I; Korsak K; Voropaev E; Osipkina O; Kovalev A
    Heliyon; 2023 Nov; 9(11):e21877. PubMed ID: 38027828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
    Vályi-Nagy I; Matula Z; Gönczi M; Tasnády S; Bekő G; Réti M; Ajzner É; Uher F
    Geroscience; 2021 Oct; 43(5):2321-2331. PubMed ID: 34633612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy.
    Matula Z; Gönczi M; Bekő G; Kádár B; Ajzner É; Uher F; Vályi-Nagy I
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm.
    Anvari E; Ghamar Talepoor A; Eshkevar Vakili M; Karimi N; Ataollahi M; Najafi G; Kabelitz D; Ahmadi I; Kalantar K
    Iran J Immunol; 2022 Sep; 19(3):321-329. PubMed ID: 36190385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2.
    Badano MN; Sabbione F; Keitelman I; Pereson M; Aloisi N; Colado A; Ramos MV; Ortiz Wilczyñski JM; Pozner RG; Castillo L; Wigdorovitz G; E de Bracco MM; Fink S; Chuit R; Baré P
    Mol Immunol; 2022 Mar; 143():94-99. PubMed ID: 35091231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of poor serologic response to COVID-19 vaccine in patients with cancer: a systematic review and meta-analysis.
    Yang W; Zhang D; Li Z; Zhang K
    Eur J Cancer; 2022 Sep; 172():41-50. PubMed ID: 35752155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 Vaccination in Patients With Malignancy; A Systematic Review and Meta-Analysis of the Efficacy and Safety.
    Javadinia SA; Alizadeh K; Mojadadi MS; Nikbakht F; Dashti F; Joudi M; Harati H; Welsh JS; Farahmand SA; Attarian F
    Front Endocrinol (Lausanne); 2022; 13():860238. PubMed ID: 35586627
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.